Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Gains from Investment Securities (2017 - 2025)

Rein Therapeutics (RNTX) has disclosed Gains from Investment Securities for 10 consecutive years, with $59310.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 97.3% to $59310.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $59310.0, a 97.3% decrease, with the full-year FY2024 number at $3.2 million, up 43.28% from a year prior.
  • Gains from Investment Securities was $59310.0 for Q3 2025 at Rein Therapeutics, down from $3.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $10.8 million in Q3 2022 to a low of $5450.0 in Q1 2024.
  • A 5-year average of $2.6 million and a median of $2.2 million in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: tumbled 98.14% in 2023, then soared 56424.44% in 2025.
  • Rein Therapeutics' Gains from Investment Securities stood at $5.4 million in 2021, then plummeted by 90.0% to $537112.0 in 2022, then crashed by 98.14% to $10000.0 in 2023, then soared by 31594.68% to $3.2 million in 2024, then tumbled by 98.13% to $59310.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Gains from Investment Securities are $59310.0 (Q3 2025), $3.1 million (Q1 2025), and $3.2 million (Q4 2024).